Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer.

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY Pharmacological Reports Pub Date : 2024-04-01 Epub Date: 2024-02-22 DOI:10.1007/s43440-024-00568-7

Xiaodong Yu, Zhongbo Du, Pingyu Zhu, Bo Liao

{"title":"Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer.","authors":"Xiaodong Yu, Zhongbo Du, Pingyu Zhu, Bo Liao","doi":"10.1007/s43440-024-00568-7","DOIUrl":null,"url":null,"abstract":"<p><p>Renal cell carcinoma (RCC) arises from the tubular epithelial cells of the nephron. It has the highest mortality rate among urological cancers. There are no effective therapeutic approaches and no non-invasive biomarkers for diagnosis and follow-up. Thus, suitable novel biomarkers and therapeutic targets are essential for improving RCC diagnosis/prognosis and treatment. Circulating exosomes such as exosomal microRNAs (Exo-miRs) provide non-invasive prognostic/diagnostic biomarkers and valuable therapeutic targets, as they can be easily isolated and quantified and show high sensitivity and specificity. Exosomes secreted by an RCC can exhibit alterations in the miRs' profile that may reflect the cellular origin and (patho)physiological state, as a ''signature'' or ''fingerprint'' of the donor cell. It has been shown that the transportation of renal-specific miRs in exosomes can be rapidly detected and measured, holding great potential as biomarkers in RCC. The present review highlights the studies reporting tumor microenvironment-derived Exo-miRs with therapeutic potential as well as circulating Exo-miRs as potential diagnostic/prognostic biomarkers in patients with RCC.</p>","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":" ","pages":"273-286"},"PeriodicalIF":3.6000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s43440-024-00568-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Renal cell carcinoma (RCC) arises from the tubular epithelial cells of the nephron. It has the highest mortality rate among urological cancers. There are no effective therapeutic approaches and no non-invasive biomarkers for diagnosis and follow-up. Thus, suitable novel biomarkers and therapeutic targets are essential for improving RCC diagnosis/prognosis and treatment. Circulating exosomes such as exosomal microRNAs (Exo-miRs) provide non-invasive prognostic/diagnostic biomarkers and valuable therapeutic targets, as they can be easily isolated and quantified and show high sensitivity and specificity. Exosomes secreted by an RCC can exhibit alterations in the miRs' profile that may reflect the cellular origin and (patho)physiological state, as a ''signature'' or ''fingerprint'' of the donor cell. It has been shown that the transportation of renal-specific miRs in exosomes can be rapidly detected and measured, holding great potential as biomarkers in RCC. The present review highlights the studies reporting tumor microenvironment-derived Exo-miRs with therapeutic potential as well as circulating Exo-miRs as potential diagnostic/prognostic biomarkers in patients with RCC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肾癌外泌体 microRNA 的诊断、预后和治疗潜力。

肾细胞癌（RCC）产生于肾小管上皮细胞。它是死亡率最高的泌尿系统癌症。目前还没有有效的治疗方法，也没有用于诊断和随访的非侵入性生物标志物。因此，合适的新型生物标志物和治疗靶点对于改善 RCC 的诊断/预后和治疗至关重要。循环外泌体，如外泌体微RNA（Exo-miRs），可提供非侵入性的预后/诊断生物标志物和有价值的治疗靶点，因为它们很容易被分离和量化，并显示出很高的灵敏度和特异性。RCC 分泌的外泌体可显示出 miRs 特征的改变，这可能反映了细胞来源和（病理）生理状态，是供体细胞的 "签名 "或 "指纹"。有研究表明，外泌体中肾脏特异性 miRs 的运输可被快速检测和测量，具有作为 RCC 生物标记物的巨大潜力。本综述重点介绍了有关具有治疗潜力的肿瘤微环境衍生 Exo-miRs 以及作为 RCC 患者潜在诊断/预后生物标志物的循环 Exo-miRs 的研究报告。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pharmacological Reports 医学-药学

CiteScore

8.40

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Pharmacological Reports publishes articles concerning all aspects of pharmacology, dealing with the action of drugs at a cellular and molecular level, and papers on the relationship between molecular structure and biological activity as well as reports on compounds with well-defined chemical structures. Pharmacological Reports is an open forum to disseminate recent developments in: pharmacology, behavioural brain research, evidence-based complementary biochemical pharmacology, medicinal chemistry and biochemistry, drug discovery, neuro-psychopharmacology and biological psychiatry, neuroscience and neuropharmacology, cellular and molecular neuroscience, molecular biology, cell biology, toxicology. Studies of plant extracts are not suitable for Pharmacological Reports.